Scientists have long been stymied in their efforts to develop effective treatments for glioblastoma multiforme, a rapidly growing cancer of the brain that patients rarely survive much longer than a year. But a flurry of recent studies exploring the genomics of the disorder offer clues about why this cancer is so aggressive, help to classify patients and their response to existing therapies, and provide much-needed new targets for experimental therapies.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Graphic Jump Location
Scientists are probing gene-gene interactions and networks to find new therapeutic targets for glioblastoma, a deadly form of brain cancer that is resistant to most existing therapies. JAMA. 2009;302(3):261-275.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 3
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.